Drotrecogin alfa Articles
Court of Appeals favors Lilly in Ariad case
6 April 2009
FDA reacts to worries about Lilly's Xigris
9 February 2009
Eight drugs get nod from EMEA's COMP
21 July 2008
Eli Lilly profit up 6% in 1st-qtr 2006
1 May 2006
Lilly swings to 4th-qtr 2005 profit
6 February 2006
Report sees "fundamental flaws" in many Rx studies; urges
5 December 2005
Lilly swings to loss in 2nd qtr on settlement
1 August 2005
Stock Commentary - New York
28 March 2005
Eli Lilly's income up 6% for 3rd-qtr 2004
1 November 2004
Strong 2003 sales for Lilly but profits flat
9 February 2004
Promising new results for Lilly's Xigris
10 November 2003
Underlying growth beats forecasts at Lilly
28 April 2003
UK NICE to view statins, antipsychotics, etc
7 April 2003
Lilly takes sepsis, ED drugs into Phase II in Japan
3 March 2003
New report sees big changes for global antibiotics market
10 February 2003
Blow for ICOS as sepsis drug fails in Phase III
6 January 2003
Lilly's Xigris OKed for BIPA Medicare payments
5 August 2002
Eli Lilly 2nd-qtr sales decrease 9%
29 July 2002
Ariad files law suit against Eli Lilly
1 July 2002
CPMP backs Xigris approval for sepsis
10 June 2002
Stock Commentary - New York
10 June 2002
Lilly's Xigris gets off to good start.
21 January 2002
Tally of NCEs in 2001 lends credence to talk of R&D productivity
21 January 2002
Stock Commentary - New York
29 November 2001
Stock Commentary - New York
22 November 2001
Chiron sepsis drug fails at final hurdle
21 November 2001
Stock Commentary - New York
1 November 2001
Xigris still on track for US approval?
23 October 2001
FDA split over Lilly's Xigris
18 October 2001
"Vast" potential for sepsis therapeutics
19 September 2001
Longer US patents on drugs and life science inventions "will cut their
18 September 2001
New drugs lift Lilly's 2nd qtr sales 16%
23 July 2001
FDA delays review of Lilly's sepsis drug
15 June 2001
Lilly's Zovant fast-tracked in USA
30 March 2001
Eli Lilly's once-weekly Prozac gains approval from US FDA
28 February 2001
Stock Commentary - New York
15 February 2001
Showing 1-52 of 52 articles
- 1
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
